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1. Introduction  
Liver transplantation has evolved as the therapy of choice for patients with end-stage 
liver disease. However, the waiting list for liver transplantation is growing at a fast pace, 
whereas the number of available organs is not growing at a proportional rate. The 
potential use of steatotic livers for transplant, one of the most common types of organs 
from marginal donors, has become a major focus of investigations. However the clinical 
problem is still unresolved since steatotic livers are more susceptible to ischemia-
reperfusion (I/R) injury and, when used, have poorer outcome than non-steatotic livers. 
Indeed, the use of steatotic livers for transplantation is associated with increased risk of 
primary non-function or dysfunction after surgery. Therefore, minimizing the adverse 
effects of I/R injury could improve outcomes in steatotic liver surgery, increase the 
number both of suitable transplantation grafts and of patients who successfully recover 
from liver transplantation.  
The present review focuses on the complexity of hepatic I/R injury, summarizing conflicting 
results obtained from the literature about the mechanisms responsible for it. We also review 
the therapeutic strategies designed in past years to reduce I/R injury, attempting to explain 
why most of them have not been applied clinically. Finally, we will consider new potential 
protective strategies that have shown promising results for I/R injury with the potential to 
increase the number of liver suitable for liver transplantation.  
2. Hepatic ischemia-reperfusion injury associated with liver transplantation. 
An unresolved problem in clinical practice  
Liver transplantation (LT) dates back to 1963, when Thomas Starzl carried out the first 
transplant on a child suffering from biliary atresia. LT has evolved as the therapy of choice 
for patients with end-stage liver disease. However, I/R injury, inherent in every LT, is the 
main cause of both initial poor function and primary non-function of liver allograft. The 
latter is responsible for 81% of re-transplantations during the first week after surgery 
(Clavien et al., 1992; Jaeschke, 1996). I/R injury is a phenomenon whereby cellular damage 
in a hypoxic organ is accentuated following the restoration of oxygen delivery (Jaeschke, 
1998; Teoh et al., 2003; Jaeschke, 2003). In the liver, this form of injury was recognized as a 
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clinically important pathological disorder by Toledo-Pereyra et al. in 1975 during studies of 
experimental LT. However, it was not until the mid-1980s that the term reperfusion injury 
was generally used in the literature on LT (Teoh et al., 2003). 
A variety of clinical factors including starvation, graft age, and steatosis contribute to 
enhance liver susceptibility to I/R injury, further increasing the patient risks related to 
reperfusion injury (Shah & Kamath, 2003). In clinical LT, starvation of the donor, due to 
prolonged intensive care unit hospitalization or lack of an adequate nutritional support, 
increases the incidence of hepatocellular injury and primary nonfunction (Massip-Salcedo et 
al., 2007).  
The waiting list for LT is growing at a fast pace, whereas the number of available organs is 
not growing at a proportional rate. The shortage of organs has led centers to expand their 
criteria for the acceptance of marginal grafts, which show poor tolerance to I/R (Busuttil & 
Tanaka, 2003). Some of these include the use of organs from aged donors, non-heart-beating 
donors (NHBD), and grafts such as small-for-size or steatotic livers. However, I/R injury is 
the underpinning of graft dysfunction that is seen in the marginal organ (Busuttil & Tanaka, 
2003). The fundamental problem with NHBD organs is the prolonged warm ischemia before 
cold preservation (Reddy et al., 2004). Controlled NHBDs provide organs that are far less 
prone to ischemic damage and tend to offer superior posttransplant function (Busuttil & 
Tanaka, 2003). The use of uncontrolled NHBDs is associated with a very high risk of 
primary nonfunction (Reddy et al., 2004).  
One of the benefits of reduced-size grafts from living donors is a graft of good quality with a 
short ischemic time, this latter being possible because live donor procurements can be 
electively timed with recipient procedure (Farmer et al., 2001). On the other hand, the major 
concern over application of living-related liver transplantation for adults is graft-size 
disparity. The small graft needs regeneration to restore the liver/body ratio. It is well 
known that I/R significantly reduces liver regeneration after hepatectomy (Franco et al., 
2004).  
Donor age of more than 70 years was found to be associated with lower patient and graft 
survival (Busuttil & Tanaka, 2003, Casillas et al., 2006). Additionally these donors also have 
an increased incidence of steatosis, which may potentiate cold preservation injury (Busuttil 
& Tanaka, 2003). Steatotic livers are one of the most common types of organs from marginal 
donors. The present review will focus on this type of liver grafts. Among other factors, 
unhealthy lifestyles associated with the consumption of alcohol and inappropriate diets 
have increased the proportion of patients with steatotic livers.  
Hepatic steatosis is a major risk factor for liver surgery and transplantation, and fatty livers 
are unsuitable for many reasons. Operative mortality associated with steatosis exceeds 14%, 
compared with 2% for healthy livers, and the risks of primary non-function and dysfunction 
after surgery are similarly higher (Casillas et al., 2006; Selzner et al., 2000). Thus, hepatic 
steatosis is the major cause of graft rejection after LT and exacerbates the organ shortage 
problem (Fernández et al., 2004). Therefore, minimizing the adverse effects of I/R injury 
could increase the number of both grafts suitable for transplantation and patients who 
successfully recover from LT. The first step towards achieving this objective is a full 
understanding of the mechanisms involved in I/R injury. 
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3. Complexity of hepatic ischemia-reperfusion injury 
A large number of factors and mediators play a part in liver I/R injury (Banga et al., 2005; 
Casillas et al., 2006; Fan et al., 1999; Jaeschke, 2003; Lentsch et al., 2000). The relationships 
between the signalling pathways involved are highly complex and it is not yet possible to 
describe, with absolute certainty, the events that occur between the beginning of reperfusion 
and the final outcome of either poor function or a non-functional liver graft.  
Figure 1 shows some of the mechanisms involved in the pathophysiology of I/R injury. Due 
to the complexity of hepatic I/R injury, the present review summarizes the established basic 
concepts of the mechanisms and cell types involved in this process. The lack of oxygen to 
hepatocytes during ischemia causes mitochondrial deenergization, ATP depletion, alterations 
of H+, Na+, Ca2+ homeostasis that activate hydrolytic enzymes and impair cell volume 
regulation and sinusoidal endothelial cells (SEC) as well as Kupffer cells (KC) swelling 
(Massip-Salcedo et al., 2007). This fact together with the imbalance between nitric oxide 
(NO) and endothelin (ET) production, contributes to narrowing of the sinusoidal lumen and 
thus to microcirculatory dysfunction. Capillary narrowing also contributes to hepatic 
neutrophil accumulation (Peralta et al., 1996; Peralta et al., 2000a). Concomitantly, the 
activation of KC releases reactive oxygen species (ROS) and proinflammatory cytokines, 
including tumour necrosis factor-α (TNF-α) and interleukin-1 (IL-1) (Bilzer & Gerber, 2000; 
Lentsch et al., 2000). ROS can also derive from xanthine deshydrogenase/xanthine oxidase 
(XDH/XOD). Cytokines release throughout the induction of adhesion molecules 
(intercellular cell adhesion molecule [ICAM] and vascular cell adhesion molecule [VCAM]) 
and chemokines promote neutrophil activation and accumulation, thereby contributing to 
the progression of parenchymal injury by releasing ROS and proteases (Jaeschke, 1998, 2003; 
Lentsch et al., 2000). Besides, IL-1 and TNF-α recruit and activate CD4+ T-lymphocytes, 
which produce granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon 
gamma (INF-Ǆ) and tumor necrosis factor beta (TNF-β). These cytokines amplify KC 
activation and TNF-α and IL-1 secretion and promote neutrophil recruitment and adherence 
into the liver sinusoids (Casillas et al., 2006; Selzner, 2003). Platelet activating factor (PAF) 
can prime neutrophils for superoxide generation, whereas leukotriene B4 (LTB4) contributes 
to the amplification of the neutrophil response (Jaeschke, 1998, 2003) (see Fig. 1). 
The present review will present data from the literature about the possible sources of ROS, 
NO effects, mechanisms, and the role of some pro-inflammatory mediators such as TNF-α, 
and transcription factors, for example, nuclear factor kappa B (NFκB). These data will 
provide a better explanation on why hepatic I/R injury remains an unresolved problem in 
the clinical practice. 
3.1 Mechanisms responsible for ROS production 
The source of ROS in hepatic I/R has long been controversial. As regards the mechanisms 
responsible for ROS production, experiments with XDH/XOD inhibitors such as allopurinol 
suggest that this system is the main ROS generator in hepatocytes and it has also been 
implicated in LT-related lung damage (Casillas et al., 2006; Fernández et al., 2002). However, 
results obtained in experimental models of the isolated perfused liver have underestimated 
the importance of the XDH/XOD system, and suggest that mitochondria could be the main 
source of ROS (Jaeschke & Mitchell, 1989). On the other hand, some data challenge the  
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Fig. 1. Summary of the mechanisms involved in hepatic ischemia-reperfusion injury. (Bilzer 
& Gerber, 2000; Casillas et al., 2006; Jaeschke, 1998, 2003; Lentsch et al., 2000; Massip-Salcedo 
et al., 2007 ; Peralta et al., 1996, 2000a; Selzner, 2003) 
pathophysiological relevance of intracellular oxidant stress during reperfusion (Grattagliano 
et al., 1999; Metzger et al., 1988). Grattagliano et al., 1999, demonstrated that mitochondria 
do not seem to actively participate in the reperfusion-induced oxidative stress. In addition, 
studies by Jaeschke et al. and Metzger et al. showed that the increased vascular oxidant 
stress after 30 and 60 min of ischemia was attenuated by inactivation of KC but not by high 
dose of allopurinol (Metzger et al., 1988). Interestingly, ROS release by KC occurs via the 
XDH/XOD system (Wiezorek et al., 1994). The conversion from XDH to XOD following cold 
storage is very slow in endothelial cells and hepatocytes, but much faster and higher in KC 
(Wiezorek et al., 1994). However, the KC function in I/R injury is still an area of active 
investigation. The elimination of KC did not modify the deleterious effects of I/R and the 
activation of neutrophils is not essential for reoxygenation injury (Imamura et al., 1995; Teoh 
et al., 2003). Clearly, then, there is a range of potentially conflicting results with regard to the 
mechanisms responsible for ROS generation in liver I/R injury. For instance, in our opinion, 
in order to clarify the importance of XDH/XOD versus mitochondria it should be taking 
into account that there are differences in the experimental models evaluated, including the 
times of ischemia. In this line, XDH/XOD play a crucial role in hepatic I/R injury only in 
conditions in which significant conversion of XDH to XOD occurs (80-90% of XOD) such as 
16 h of cold ischemia. However, this ROS generation system does not appear to be crucial at  
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shorter ischemic periods such as 6 h of cold ischemia (Fernández et al., 2002). Thus, even 
after prolonged periods of ischemia, where a significant conversion of XDH to the XOD 
occurs, this enzyme may only play a minor role compared with mitochondria (Jaeschke & 
Mitchell, 1989). In contrast with the experimental studies, the clinical reports suggest that 
45-65% XOD was sufficient to induce hepatic damage (Pesonen et al., 1998). In addition, the 
drugs used for inhibiting XDH/XOD should be considered, since, for example allopurinol, 
seems to have more than one mechanisms of action. It is not only a potent inhibitor of XOD, 
but it may also improve ischemia-induced mitochondrial dysfunction (Casillas et al., 2006; 
Jeon et al., 2001). In fact, evidence for reduced mitochondrial dysfunction after high doses of 
allopurinol was shown in a warm hepatic I/R model (Jeon et al., 2001). Similarly, in 
assessing the relative contribution of intracellular versus vascular oxidant stress to hepatic 
I/R injury, it should also be noted that oxidative stress in hepatocytes and the stimulatory 
state of KC after I/R depend on the duration of ischemia, and may also differ between 
ischemia at 4ºC and that at 37ºC, which probably leads to different developmental 
mechanisms of liver damage (Casillas et al., 2006). The differences in KC function in liver 
I/R injury cannot be attributed to the type experiment, since most authors used an ex vivo 
model of perfused rat liver. Nor could they be explained by differences in the times of cold 
ischemia, since the results obtained following the same ischemic period (24 h) were 
completely opposed (Imamura et al., 1995). The type of drug used for KC inactivation is the 
most probable explanation, since most of the studies implicating KC as main source of ROS 
used gadolinium chloride (GdCl3) (Schauer et al., 2001; Zhong et al., 1996) whereas those 
that did not implicate KC used liposome-encapsulated dichloromethylene diphosphate 
(Imamura et al., 1995). Indeed, differences in the properties and action mechanisms of these 
two KC inhibitors have been reported.  
3.2 Mediators and transcription factors in I/R injury 
3.2.1 Nitric oxide 
It is difficult to distinguish between beneficial and harmful mediators in I/R injury. Some 
authors have found that NO exerts a beneficial effect on I/R injury in different organs, 
tissues and cells, whereas other studies report no effect or even a deleterious action of NO 
(Peralta et al., 2001a). In our opinion, in addition to the differences in animal species, 
experimental models of hepatic I/R tested, and the dose and timing of administration of the 
different pharmacological modulators of NO, these differential effects of NO could be 
explained, at least partially, by the different source of NO. In this context, some studies 
suggest that although endothelial NO synthase (eNOS)-derived NO production is protective 
in I/R, inducible NO synthase (iNOS)-derived NO production may contribute to I/R injury. 
This may be a function of the NO generation kinetics of the two isoforms in I/R. The basal, 
low-level NO generation by the constitutively expressed eNOS isoform may abrogate the 
microcirculatory stresses of engraftment and reperfusion. In contrast, iNOS-derived NO 
cannot be generated until several hours after stimulation because of requirements for 
transcriptional induction of this isoform. Excess NO production may no longer be of 
microcirculatory benefit at this later time (Shah & Kamath, 2003). Furthermore, the excessive 
levels of iNOS-derived NO production may be detrimental through the generation of NOS-
derived superoxide production or the generation of peroxynitrite. Additionally, whether 
NO is cytoprotective or cytotoxic in hepatic I/R injury may be determined at apoptosis 
(Casillas et al., 2006). For example, NO may promote apoptosis by inducing cytochrome c 
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(Cyt c) release and caspase activation (Chung et al., 2001). However, NO may also 
upregulate the anti-apoptotic protein Bcl-2 (Genaro et al., 1995). In addition, to understand 
the different results in relation with the action mechanisms of NO, it is important to clarify 
whether the NO source is endogenous or exogenous. In this regard, although the beneficial 
role of endogenous NO could be related to an attenuation of leukocyte accumulation, the 
exogenous supplementation of NO did not modify this parameter but was associated with 
an inhibition of endothelin release (Peralta et al., 2001a). 
3.2.2 TNF and NFκB 
Differential effects of NO mentioned above have also been reported for other mediators 
involved in hepatic I/R injury. According to the cell type and experimental or pathologic 
conditions, TNF-α is protective or injurious to the liver in the context of I/R injury. TNF-α 
may stimulate cell death or it may induce hepatoprotective effects mediated by antioxidant, 
antiapoptotic, and other anti-stress mediators coupled with a pro-proliferative biologic 
response (Casillas et al., 2006). For example, although the deleterious effect of the TNF-α in 
local and systemic damage associated with hepatic I/R is well established (Peralta et al., 
1999), this mediator is also a key factor in hepatic regeneration (Teoh et al., 2003), an 
important process in reduced-size LT. Conversely, a study by our group found no 
correlation between TNF-α levels and liver regeneration in reduced-size LT (Franco et al., 
2004), while Tian et al., 2006, linked disruption of TNF-α release to lower hepatic injury and 
increased liver regeneration. These divergent results about the role of TNF-α in liver 
regeneration could be explained by different TNF-α inhibitors or animal species utilized in 
these experiments as well as differences in the experimental models of LT used, including 
the times of cold ischemia. These differential effects observed for TNF-α can also be 
extrapolated to transcription factors.  
It is well known that NFκB can regulate various downstream pathways and thus has the 
potential to be both pro- and antiapoptotic (Fan et al., 1999). Currently it is not clear whether 
the beneficial effects of NFκB activation in protection against apoptosis or its detrimental 
proinflammatory role predominate in liver I/R (Fan et al., 1999). Hepatic neutrophil 
recruitment and hepatocellular injury are significantly reduced when NFκB activation is 
suppressed in mice following partial hepatic I/R (Casillas et al., 2006). However, nuclear 
factor kappa B (NFκB) activation is essential for hepatic regeneration after rat LT, and 
reduces apoptosis and hepatic I/R injury (Bradham et al., 1999). To understand the role of 
NFκB in the context of hepatic I/R, is important to consider the differences in animal species 
used, for instance, mechanisms of protection from apoptosis might be different in rats and 
mice (Chaisson et al., 2002). In addition, the experimental design used to evaluate the role of 
this transcription factor may also be important. Thus, some studies using adenoviral vector 
containing a repressor to prevent NFκB activation may not accurately reflect the role of 
NFκB signalling in regenerating liver because adenoviral vectors themselves cause increased 
TNF-α levels, DNA synthesis, and apoptosis in the liver before partial hepatectomy (Iimuro 
et al., 1998). Moreover, to explain these apparently controversial effects of NFkB, the pattern 
of NFkB activation under cold ischemia conditions should be taken into account. Takahashi 
et al., 2002, have demonstrated in rat LT that NFkB activation during reperfusion occurs in 
two phases. The early peak of NFkB DNA binding was found 1-3 h after reperfusion and 
represents the nuclear translocation of NFkB p50/p65 heterodimers, whereas the second  
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peak, mainly composed of p50 homodimers, was observed at 12 h post-reperfusion. In this 
study, the donor liver treatment with adenovirus encoding the IkB super-repressor gene 
cannot affect the early peak of NFkB activation, but partially inhibited the second peak of 
NFkB DNA binding. The results indicated that, in contrast to early NFkB activation, 
inhibition of the late phase of NFkB activation was not associated with variations in levels of 
inflammatory mediators, but rather enhanced hepatocellular apoptosis (Takahashi et al., 
2002), which reinforces the dual function of NFkB in transplanted liver. Nevertheless, this 
hypothesis does not fully explain the differences in the results. Indeed, Bradham et al., 1999, 
observed a marked increase in apoptosis when NFkB blockade was carried out at 3 h of 
reperfusion, which seems to be a reperfusion time associated with the early peak of 
activation of NFkB. Of course, there are differences between Takahashi´s and Bradham´s 
studies. For example, whereas Bradham infused the adenoviral vector by endovenous 
injection 24 h before liver explantation, in Takahashi’s study the graft was perfused with 
UW solution containing the adenovirus immediately before cold storage.  
3.2.3 Neutrophil accumulation 
Activation of neutrophils has been implicated in the hepatic microvascular dysfunction and 
parenchymal damage associated with I/R (Cutrin et al., 2002). Still, a controversial topic is 
the question of how neutrophils actually accumulate in the liver. The classical theory argues 
that the increased expression of adhesion molecules such as ICAM-1 and P-selectin plays a 
key role in neutrophil accumulation and the subsequent liver damage associated with I/R 
(Banga et al., 2005, Cutrin et al., 2002). In contrast, it has also been reported that neutrophil 
accumulation observed in the liver following I/R is not dependent on the up-regulation of 
either ICAM-1 or P-selectin (Peralta et al., 2001b).  
To explain the results that neutrophil accumulation is not dependent on adhesion molecules, 
we subscribe to the theory proposed by Jaeschke, 2003. This theory argues that although P-
selectin and ICAM-1 appear to be relevant for neutrophil adherence in postsinusoidal 
venules, the neutrophils relevant for the injury accumulate in sinusoids, which were 
identified as the dominant sites for neutrophil extravasation. In these capillaries, neutrophil 
sequestration does not depend on B2 integrins or on ICAM-1 or selectins (Essani et al., 1998; 
Vollmar et al., 1995; Jaeschke et al., 1996). Thus, mechanical factors such as active 
vasoconstriction, vascular lining cell swelling and injury, and reduced membrane flexibility 
after activation of the neutrophil, appear to be involved in trapping of these leukocytes in 
sinusoids (Jaeschke et al., 1996). The extensive vascular injury during reperfusion eliminates, 
in part, the sinusoidal endothelial cell barrier and the neutrophil has direct access to 
hepatocytes (Jaeschke, 2003; McKeown et al., 1988). Nevertheless, even with damaged but 
still present EC, transmigration may still be required (Jaeschke, 1998). As a consequence, I/R 
injury is only moderately or not at all attenuated by anti-ICAM therapies (Farhood et al., 
1995; Vollmar et al., 1995). In regard with the role of P-selectin, sinusoidal EC neither 
contain Weibel Palade bodies nor do they transcriptionally upregulate relevant levels of P-
selectin (Essani et al., 1998). However, during I/R, a number of interventions directed 
against selectins reduced hepatic neutrophil accumulation and cell injury (Amersi et al., 
2001). Because these findings cannot be explained by the prevention of P-selectin-dependent 
rolling in sinusoids, it has been suggested that most liver I/R models include some degree 
of intestinal ischemia, which leads to neutrophil accumulation in remote organs including 
the liver (Casillas et al., 2006; Kubes et al., 2002). Thus the lower number of neutrophils in 
www.intechopen.com
 Liver Transplantation – Basic Issues 
 
28 
the liver when selectins are blocked may be a secondary effect due to the protection of 
antiselectin therapy against intestinal reperfusion injury (Kubes et al., 2002).  
3.3 Cell death in liver transplantation 
The severity of hepatocyte damage depends on the length of time the ischemia lasts. In 
human LT, a long ischemic period is a predicting factor for post-transplantation graft 
dysfunction, and some transplantation groups hesitate to transplant liver grafts preserved 
for more than 10 h (Fernández et al., 2002). Some studies in experimental models of LT 
indicate that 24 h of cold ischemia induces low survival at 24 h after LT. However, at shorter 
ischemic periods, LT may also result in primary organ dysfunction. The main victims of 
ischemic injury are the hepatocytes and SECs. These two cell types show different responses 
to different types of ischemia: hepatocytes are more sensitive to warm ischemia and SECs to 
cold ischemia (Bilzer & Gerber, 2000; McKeown et al., 1988). Although most hepatocytes 
remain viable after 48 h of cold preservation and reperfusion, SECs suffer severe damage 
following reperfusion (40% non-viable) (Caldwell et al., 1989). The result of this sinusoidal 
damage is the subsequent microcirculatory abnormalities upon reperfusion, resulting in 
hepatocyte injury and dysfunction (McKeown et al., 1988). This contributes to the 
development of primary nonfunction or impaired primary function after LT. However, 
some studies have called the importance of sinusoidal injury into question. Huet et al., 2004, 
have demonstrated that damage to the extracellular matrix from prolonged preservation 
and reperfusion appears to be the critical factor in graft failure (Banga et al., 2005). In 
addition, it is possible that perturbations in hepatocyte levels of adenine nucleotides during 
cold storage can trigger proteolytic events that contribute to damage in the liver graft and 
subsequently compromise hepatic functions after LT (Kukan & Haddad, 2001). Moreover, 
cold ischemia profoundly disturb several key hepatocellular functions, such as volume and 
pH homeostasis, as well as solute transport and drug metabolism, protein synthesis and 
mitochondrial function. This contributes to preservation injury of the liver graft. Therefore, 
these observations indicate that aside from reducing EC damage, LT therapy may benefit 
from strategies aimed at improving the maintenance of appropriate hepatocyte functions 
(Kukan & Haddad, 2001; Vajdova et al., 2002).  
Apoptosis has been regarded as the fate of cells experiencing I/R injury (Sasaki et al., 1996). 
In this line, different studies have demonstrated apoptotic death in hepatocytes and/or 
SECs after both cold and warm ischemia of the rat liver (Gao et al., 1998; Kohli et al., 1999). 
All of the aforementioned studies (Gao et al., 1998; Kohli et al., 1999; Sasaki et al., 1996) used 
TdT-mediated dUTP-biotin nick and labelling (TUNEL staining) for DNA ladders to 
demonstrate apoptosis. However, the ability of TUNEL staining to distinguish between 
apoptosis and necrosis has been called into question. The activation of caspases has also 
been used to demonstrate apoptosis in rat SECs following cold I/R (Natori et al., 1999). 
Indeed, use of pan-caspase inhibitors protected rat liver SECs and hepatocytes against I/R 
injury after prolonged periods of both cold and warm ischemia. On the other hand, other 
groups oppose the view that the majority of cells undergo apoptosis in response to either 
warm or cold I/R injury, believing that necrosis is the principle form of cell death (Massip-
Salcedo et al., 2007). They believe that in a number of studies the proportion of cells 
undergoing apoptosis is not of significant magnitude and that the degree of caspase 
activation does not correlate with the number of SECs and hepatocytes supposedly 
undergoing apoptosis. Thus, a controversy has emerged over the past years as to whether 
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necrotic or apoptotic cell death accounts for the severe parenchymal injury observed during 
hepatic reperfusion. Although it has long been assumed that necrosis and apoptosis are 
different processes this may not actually be the case. First we will briefly review some basic 
background information on death cell signalling pathways in hepatocytes in order to 
understand the shared pathway that leads to both necrosis and apoptosis.  
Apoptosis occurs through two main pathways. The first, referred to as the intrinsic 
(mitochondrial) pathway, is typically activated by a variety of stressors such as DNA 
damage, p53 activation, growth factor deprivation, and metabolic disturbances (Malhi et al., 
2006). The second is the extrinsic pathway that is triggered through death receptors (Malhi 
et al., 2006). It is well known that one of the most important regulators of intrinsic pathway 
is the Bcl-2 family of proteins. The Bcl-2 family includes proapoptotic members such as Bax, 
Bak, Bad, Bid and antiapoptotic members such Bcl-2, Bcl-Xl and Bcl-W (Ghobrial et al., 
2005). Following death signal, proapoptotic proteins undergo posttranslational 
modifications resulting in their activation and translocation to the mitochondria. Then, the 
outer mitochondrial membrane becomes permeable, leading to the release of Cyt c, which 
promotes caspase 9 activation, which then activates caspase 3 and the final stages of 
apoptosis (Ghobrial et al., 2005). In the extrinsic pathway, a variety of mediators, including 
tumor TNF-α, Fas ligand, and tumour necrosis factor-related apoptosis-inducing ligand 
(TRAIL) first bind to their respective death receptors, which cause receptor oligomerization 
and the association of various adapter proteins, including Fas-associated death domain, 
TNF-α receptor-associated death domain, and TNF-α receptor-associated factor. Fas-
associated death domain and TNF-α receptor-associated death domain promote binding of 
procaspase 8 and its proteolytic activation to catalytic caspase 8. If sufficient amounts of 
caspase 8 are generated at the receptor, caspase 8 can directly activate procaspase 3. In 
hepatocytes the caspase 8 interacts with the intrinsic pathway and cleaves Bid, a BH3 only 
proapoptotic Bcl2 family member, to a truncated form, tBid. tBid translocates to 
mitochondria, causing mitochondrial permeabilization and release of mitochondrial 
effectors of apoptosis, such Cyt c (Yin, 2000) (see Fig. 2).  
The mechanisms that induce the release of mitochondrial intermembrane proteins such as 
Cyt c remain controversial (Jaeschke & Lemasters, 2003). In hepatocytes TNF-α and Fas 
dependent signalling induce the onset of the mitochondrial permeability transition (MPT), 
which leads to large-amplitude mitochondrial swelling, rupture of the outer membrane, and 
release of Cyt c and other proteins from the intermembrane mitochondrial space (Jaeschke & 
Lemasters, 2003). In some models, tBid interaction with either Bax or Bak, forms channels in 
the mitochondrial outer membrane that release Cyt c and other proteins from the 
intermembrane space. If MPT onset occurs in relatively few mitochondria, the organelles 
become sequestered into autophagosomes for lysosomal digestion, a process that eliminates 
the damaged and potentially toxic mitochondria (Casillas et al., 2006; Jaeschke & Lemasters, 
2003). When the MPT involves more mitochondria, mitochondrial swelling leads to outer 
membrane rupture and Cyt c realease. Provided that ATP is available from glycolysis and 
still-intact mitochondria, Cyt c activate downstream caspases and other executioner 
enzymes of apoptosis. When MPT onset is abrupt and involves most mitochondria, ATP 
becomes profoundly depleted, which blocks caspase activation. Instead, ATP depletion 
culminates with plasma membrane rupture and the onset of necrotic cell death (Jaeschke & 
Lemasters, 2003). Hence, the new term “necrapoptosis” has been coined to describe a 
process that begins with a common death signal and which culminates in either cell lysis 
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(necrotic cell death) or programmed cellular resorption (apoptosis), depending on factors 
such as the decline of cellular ATP levels (see Fig. 2). 
 
Fig. 2. Scheme of possible cell death pathway in hepatic I/R. (Alfany et al., 2009; Ben 
Mosbah et al., 2010; Casillas et al., 2006; Fernández et al., 2004; Ghobrial et al., 2005; Jaeschke 
&Lemasters, 2003; Malhi et al., 2006; Massip-Salcedo et al., 2007; Selzner et al., 2000; Yin, 
2000) 
4. Steatosis in hepatic ischemia-reperfusion 
Several hypotheses have been suggested to explain the decreased tolerance of steatotic liver 
to I/R injury compared with non-steatotic livers. The impairment of the microcirculation is 
considered a major event of reperfusion injury in steatotic livers (Ijaz et al., 2003). A 
reduction in hepatic microcirculation has been observed in human fatty donor livers and in 
experimental models of hepatic steatosis (Ijaz et al., 2003; Seifalian et al., 1999). An 
imbalance between vasoconstrictors (e.g., ET1) and vasodilators (e.g., NO) negatively affect 
the hepatic microcirculation (Massip-Salcedo et al., 2007; Peralta et al., 2000a). In addition, 
fatty accumulation in the cytoplasm of hepatocytes is associated with an increase in cell 
volume that reduces the size of the hepatic sinusoid space by 50% compared with a normal 
liver and may result in partial or complete obstruction of the hepatic sinusoid space (Ijaz et 
al., 2003; Seifalian et al., 1999). Using Doppler flowmetry, Seifalian et al., 1999 demonstrated 
reduced sinusoidal perfusion in fatty human liver donors compared with healthy livers. 
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Analogous studies in rabbits with diet-induced steatosis confirmed that this reduction in 
perfusion correlated with the severity of fat accumulation in hepatocytes. The reductions in 
sinusoidal perfusion appear to arise initially from the effects of enlarged hepatic 
parenchymal cells, swollen with accumulated lipid, which widen the parenchymal cell 
plates and narrow and distort the lumens of sinusoids. Other investigators have shown that 
as a result of the structural alterations around them, the sinusoids become inefficient 
conduits of blood with resulting impairment of tissue perfusion, evidenced by the 
significant reductions in the numbers of perfused sinusoids per microscopic field (Teoh et 
al., 2010). 
Hepatocyte damage appears remarkably higher in steatotic livers than in non-steatotic livers 
(Casillas et al., 2006; Selzner et al., 2000). Several evidences indicate that an increased 
sensitivity of fatty hepatocytes to the injurious effects of ROS could explain the poor 
tolerance of steatotic livers to I/R (Koneru et al., 2005; Soltys et al., 2001). It has been 
postulated that steatotic livers are more susceptible than nonsteatotic livers to lipid 
peroxidation because of either their lower antioxidant defenses or their greater production 
of ROS or both (Fernández et al., 2004). Mitochondrial ROS generation dramatically 
increases during reperfusion and mitochondrial structures are exposed to the attack of the 
ROS generated both outside and inside these organelles leading eventually to the 
dysfunction of important mitochondrial processes including those responsible for the ATP 
synthesis. In ROS generation systems, the inhibition of XOD with allopurinol effectively 
protected against the greater liver and lung damage in transplantation of steatotic livers 
(Fernández et al., 2004). Higher levels of IL-1ǃ and lower IL-10 levels were observed in 
steatotic livers compared with non-steatotic livers after I/R. This imbalance between pro- 
and anti-inflammatory ILs was responsible for the vulnerability of steatotic livers to I/R 
(Serafin et al., 2004). Previous studies form our group indicated less glutathione (GSH) and 
SOD levels in steatotic livers than in non-steatotic livers as consequence of hepatic I/R 
(Fernández et al., 2004; Serafin et al., 2002).  
It is well-known that steatotic livers synthesise less ATP than non-steatotic livers during 
post-ischemic reperfusion (Caraceni et al., 2005). Fatty degeneration induces a series of 
ultra-structural and biochemical alterations in both human and animal mitochondria. The 
lower ATP and adenine nucleotide content observed in steatotic livers preserved in UW 
solution could be caused by mitochondrial damage (Ben Mosbah et al., 2006; Caraceni et al., 
2005; Massip-Salcedo et al., 2007). Caraceni et al., 2004 reported that alterations in oxidative 
phosphorylation during preservation is greatly enhanced by fatty infiltration resulting from 
damage to respiratory chain complex I and F0F1–ATP synthase. Others studies have 
discovered that in steatotic livers under conditions of either warm ischemia or 
transplantation, the content of mitochondrial uncoupling protein-2 (UCP-2) is four to five 
times higher than in non-steatotic livers (Chavin et al., 2004; Wan et al., 2008). This finding 
was associated with reduced ability to synthesize ATP upon reperfusion (Chavin et al., 
2004). If cold storage time exceeds 10-12 h, complications in biliary structures occur in more 
than 25% of liver transplant recipients (Kukan & Haddad, 2001). Several factors, including 
poor recovery after ATP depletion appear to contribute to bile duct cell damage after liver 
transplantation. Furthermore, isolated rat bile duct epithelial cells are noticeably sensitive to 
oxidative stress, possibly because their cellular stores of reduced glutathione are seven times 
lower than those of hepatocytes (Noack et al., 1993). Taking these observations into account, 
bile production failure in steatotic livers could be explained, at least partially, by the lower 
www.intechopen.com
 Liver Transplantation – Basic Issues 
 
32 
ATP and increased oxidative stress presented by this type of liver compared with non-
steatotic liver.  
Toll-like receptor 4 (TLR4) has been implicated as a mediator of steatotic liver damage after 
I/R (Ellett et al., 2009). The loss of TLR4 in steatotic livers from TLR4-knockout HFD 
animals reduces pro-inflammatory cytokines and liver injury and improves survival (Ellett 
et al., 2009). Although TLR4 signaling is relevant in hepatic I/R injury, there is some 
controversy over which of the pathways [(myeloid differentiation factor 88 (My-D88)-
dependent) or Toll/IL-1 receptor domain-containing adaptor inducing interferon-ǃ 
(TRIF/IRF-3 signalling pathway)] is activated in hepatic I/R (Kang et al., 2011). Neutrophils 
have been involved in the increased vulnerability of steatotic livers to I/R injury, especially 
in alcoholic steatotic livers. However, neutrophils do not account for the differentially 
greater injury in the non-alcoholic steatotic liver during the early or late hours of 
reperfusion. Similarly, the role of TNF-α in the vulnerability of steatotic livers to I/R injury 
may be dependent on the type of steatosis (Serafin et al., 2002). These observations could be 
of clinical interest because pharmacological strategies that could be effective in alcoholic 
fatty livers by reducing the neutrophil infiltration and or TNF-α action may not be sufficient 
to reduce the hepatic I/R injury in non-alcoholic fatty livers. 
Cell death can occur by either necrosis or apoptosis and intracellular ATP level appear to 
play a role as a putative apoptosis/necrosis switch: when ATP depletion is severe, necrosis 
ensues before the activation of the energy-requiring apoptotic pathway (Casillas et al., 2006; 
Massip-Salcedo et al., 2007) (See Fig. 2). In steatotic liver graft undergoing 6 h of cold 
ischemia, necrosis was the predominant cell death whereas no apoptosis signs were found 
(Alfany et al., 2009; Fernández et al., 2004). Since apoptosis is an energy-requiring process, 
the impaired maintenance of ATP levels observed after reperfusion in steatotic livers 
submitted to long periods of cold ischemia may be linked with a failure to induce apoptosis. 
Thus, it is not surprising that data reported previously indicate that necrosis rather than 
apoptosis is the predominant process by which steatotic livers undergo cell death (Alfany et 
al., 2009; Fernández et al., 2004; Selzner et al., 2000).  
Previous studies from our group have indicated that steatotic livers differed from non-
steatotic livers in their response to UPR and ER stress. Steatotic livers showed a reduced 
ability to respond to ER stress as the activation of two UPR arms, IRE1 and PERK, was 
weaker in the presence of steatosis. (Ben Mosbah et al., 2010). Different hypotheses, 
including decreased ATP production and dysfunction of regulators of apoptosis, such as 
Bcl-2, Bcl-xL and Bax have been proposed to explain the failure of apoptosis in steatotic 
livers. The results on ER stress in steatotic livers undergoing I/R may throw some light on 
this question. Reduced proapoptotic factors related to ER stress such as caspase 12, C/EDP-
homologos protein (CHOP) and Jun N-terminal kinase (JNK) were observed in steatotic 
livers under conditions of I/R compared with non-steatotic livers. This may be related to the 
reduced activation of the two UPR arms, inositol-requiring enzyme-1 (IRE1) and PERK, 
which are responsible for caspase 9 and 12 activation, JNK activation and CHOP induction 
(Ben Mosbah et al., 2010) (see Fig. 2). We believe that the damaged ER and mitochondria are 
intimately linked and that mitochondrial cell death and ER-induced cell death cannot be 
separated in hepatic I/R. Thus, caspase activation and Cyt c release from mitochondria 
consequently to hepatic I/R (Ben Mosbah et al., 2010) can be attributed to ischemic 
disturbance or damage to the ER. Given these results in steatotic livers under warm 
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ischemia conditions, it is therefore tempting to speculate that increased ER stress may be 
involved in the vulnerability of steatotic liver grafts to I/R injury associated with 
transplantation and in the sensitivity of other marginal grafts to I/R injury, such as liver 
grafts from aging donors. Indeed, aging donors have an increased incidence of steatosis, 
which may favor cold preservation injury (Busuttil & Tanaka, 2003; Massip-Salcedo et al., 
2007). Alterations in the activation of inflammatory transcription factors and expression of 
cytoprotective proteins, increased intracellular oxidants and decreased mitochondrial 
function and protein misfolding accumulation, and aggregation also characterize many age-
related diseases (Massip-Salcedo et al., 2007; Pallet et al., 2009). 
5. Strategies designed in past years to prevent hepatic I/R injury 
Despite improvements in pharmacological treatments, preservation solutions and gene 
therapy aimed at reducing hepatic I/R injury, the results to date have not been conclusive. 
Figure 3 shows some of the therapeutic strategies developed to prevent I/R injury in LT. 
Possible reasons for the failure of these strategies in clinical applications are now 
discussed.  
5.1 Pharmacological treatment 
Numerous experimental studies have focused on inhibiting the harmful effects of I/R-
associated inflammatory response. In this respect, drugs such as chloroquine and 
chlorpromazine have been administered in order to prevent mitochondrial dysfunction and 
loss of liver cell phospholipids during hepatic ischemia. Antioxidant therapy using either 
tocopherol, GSH ester, or allopurinol has been applied in an attempt to inhibit ROS effects in 
reperfusion, and anti-TNF antiserum pre-treatment has also been employed to block the 
damaging effects of this cytokine. Therapies with dopamine or ATP-MgCl2 have been 
administered to reduce hepatic I/R injury-related microcirculatory disorders. Drugs such as 
adenosine, NO donors, L-arginine, and anti-ICAM-1 and anti-P-selectin antibodies have 
been used to inhibit neutrophil accumulation. However, none of these treatments has 
managed to prevent hepatic I/R injury. The possible side effects of the some drugs may 
frequently limit their use in human LT (Casillas et al., 2006). For example, idiosyncratic liver 
injury in humans is documented for chlorpromazine, pernicious systemic effects have been 
described for nitric oxide (NO) donors, allopurinol therapy can cause haematological 
changes and gadolinium can induce coagulation disorders (Casillas et al., 2006).  
Hepatic failures have been observed after administration of these two thiazolidinediones 
(TZDs) and some case reports of acute hepatotoxicity attributed to rosiglitazone have been 
published, including one death (Reynaert et al., 2005). The toxicity of TZDs is thought to be 
mainly metabolic idiosyncratic, although in some cases possible immunological mechanism 
has been implicated (Reynaert et al., 2005). High dose resveratrol was found to be a pro-
oxidant with aggravation of liver injury; and experiments are in progress to devise a 
pharmaceutical form appropriate for clinical use (Hassan et al., 2008). The development of 
therapeutic strategies that utilize the protective effect of Heme oxigenase-1 (HO-1) induction 
is hampered by the fact that most pharmacological inducers of this enzyme perturb organ 
function by themselves and that gene therapy for up-regulation of HO-1 has potential 
negative side effects, which currently preclude its clinical application under these conditions 
(Schmidt, 2010) (see Fig. 3). 
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Fig. 3. Strategies used to prevent hepatic I/R injury. (Sp, species). (Carini et al., 2004; 
Carrasco et al., 2005; Casillas et al., 2006; Chavin et al., 2004; Cheng et al., 2003; Esfandiari et 
al., 2007; Fan et al., 1999; Hassan et al., 2008; Massip-Salcedo et al., 2006; Nakano et al., 2007; 
Natori et al., 1999; Peralta et al., 2001a, 2001b; Polyak et al., 2000; Reynaert et al., 2005; 
Schmidt, 2010; Selzner et al., 2000, 2003; Teoh et al., 2003; Vajdova et al., 2002; Yoshinari et 
al., 2001) 
The difficulty of blocking the inflammation related to this process must be taken into 
account because, among other factors, many mediators and cell types are involved in this 
kind of inflammatory response. Pharmacological treatment-derived difficulties must also be 
considered. In this regard, superoxide dismutase (SOD) and glutathione show inadequate 
delivery to intracellular sites of ROS action (Polyak et al., 2000). The administration of anti-
TNF antibodies does not effectively protect against hepatic I/R injury, and this finding has 
been related to the failure of complete TNF-α neutralization locally (Peralta et al., 2001b). 
Additionally, special attention should be given to drugs that suppress TNF-α, because its 
potential dual effects (Teoh et al., 2003). Small changes in the dose of NO donors produce 
totally opposite effects (Peralta et al., 2001a). Although this also occurs in non-steatotic 
livers, modulating I/R injury in steatotic livers poses a greater problem. Until now, data 
about the effectiveness of the administration of antioxidants on the deleterious effects of 
ROS in steatotic livers was controversial. Some studies in obese Zucker rats, a well-
characterized model of nutritionally induced obesity, indicated that the administration of 
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tocopherol, which possesses antioxidant properties, improved tolerance to warm ischemia. 
However, other experimental studies in steatotic livers, induced by a choline–methionine-
deficient diet, show that the administration of GSH precursors, such as N-acetylcysteine, 
could help to restore hepatocellular integrity in the steatotic liver but without scavenging 
free radical. In addition, both dietary high fat and alcohol exposure produced SOD/catalase-
insensitive ROS that may be involved in the mechanism of failure of steatotic livers after 
orthotopic LT (Casillas et al., 2006; Massip-Salcedo et al., 2007; Serafin et al., 2002; Soltys et 
al., 2001).  
Differences in the action mechanisms between steatotic and non-steatotic livers mean that 
therapies which are effective in non-steatotic livers may prove useless in the presence of 
steatosis, and the effective drug dose may differ between the two liver types. Findings 
such as these must be taken into consideration when applying pharmacological strategies 
in the same way to steatotic and non-steatotic livers, because the effects may be very 
different. Apoptosis was the predominant form of hepatocyte death in the ischemic non-
steatotic liver, whereas the steatotic livers developed massive necrosis after an ischemic 
insult. Thus, caspase inhibition, a highly protective strategy in non-steatotic livers, had no 
effect on hepatocyte injury in steatotic livers (Selzner et al., 2000). For instance, whereas in 
an LT experimental model a NO donor reduced oxidative stress in non-steatotic livers, the 
same dose increased vulnerability of steatotic grafts to I/R injury (Carrasco et al., 2005). 
The injurious effects of exogenous NO donors on hepatic injury and oxidative stress in 
steatotic grafts could be explained by peroxinitrite generation caused by ROS 
overproduction (Carrasco et al., 2005). HO-1 activators such as cobalt (III) protoporphyrin 
IX, might protect both liver types against warm I/R injury. However, a lower dose of HO-
1 activator was required to protect steatotic livers effectively, as steatotic livers 
undergoing I/R showed higher HO-1 levels than nonsteatotic livers (Massip-Salcedo et 
al., 2006). Furthermore, there may be drugs that would only be effective in steatotic livers. 
In the context of LT, steatotic donors have been reported to show a higher content of 
mitochondrial uncoupling protein-2 (UCP-2) and a reduced ability to synthesize ATP 
upon reperfusion, thus leading to increased mortality following I/R (Cheng et al., 2003). 
Studies by Chavin et al have discovered that in ob/ob mice (approximately 70%-80% of 
liver lipid content) expression of UCP-2 is four to five times higher than in normal liver 
tissues (Chavin et al., 1999; Wan et al., 2008). Hence, compounds such as cerulenin that 
reduce UCP-2 expression in steatotic livers, offer protection as a result of increased 
availability of ATP prior to I /R (Chavin et al., 2004). However, this strategy may be 
ineffective in non-steatotic livers because the latter do not show an overexpression of 
UCP-2 (Chavin et al., 1999). Similar results have been obtained with carnitine 
administration (Tolba et al., 2003; Yonezawa et al., 2005).  
All the aforementioned results point up the fact that the different mechanisms of cell death 
in steatotic vs. non-steatotic livers as well the differences in the mechanisms involved in 
hepatic I/R injury in terms of the type of steatosis could explain the difficulties in effectively 
preventing steatotic livers from I/R injury. Further investigations are required to optimize 
some treatments because long-term therapy appears to be necessary to exert the desired 
effects. For example, the pre-treatment times for rosiglitazone was between 6 to 12 weeks 
(Nakano et al., 2007); and, S-adenosylmethionine (SAM) between 14 and 17 weeks 
(Esfandiari et al., 2007). Similarly, long-term IL-6 treatment (10 days) reduced hepatic 
steatosis and markedly prevents I/R-induced liver injury in ob/ob mice and mice fed high-
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fat diets (Hong et al., 2004). However, there are obvious difficulties concerning the 
feasibility of long-term drug administration in some I/R processes, in particular, liver 
transplantation from cadaveric donors, because this is an emergency procedure in which 
there is very little time to pre-treat the donor with drugs.  
5.2 Preservation solutions 
Since its introduction by Belzer et al. in the late eighties, the University of Wisconsin (UW) 
solution has become the standard solution for the preservation of most organs in 
transplantation. The inclusion of some components in the UW solution has been both 
advocated and criticised. For instance, adenosine has been added to UW solution as a 
substrate for the regeneration of adenine nucleotides. However, simplified variants of UW 
solution in which adenosine was omitted were shown to have similar or even higher 
protective potential during cold liver storage. The colloid hydroxyethyl starch (HES) 
included in UW preservation solution prevents interstitial edema but produces extended 
and accelerated aggregation of erythrocytes that may result in stasis of blood and 
incomplete washout of donor organs before transplantation. Another limitation of the UW 
solution is that some of its constituent compounds (allopurinol, lactobionate) do not offer 
very good protection because they are not present at a suitable concentration and encounter 
problems in reaching their site of action. Indeed, studies in humans have suggested that the 
allopurinol in the UW preservation solution was unable to prevent the subsequent 
XDH/XOD-derived superoxide radical production during reperfusion (Casillas et al., 2006; 
Pesonen et al., 1998). 
A variety of ingredients such as stable protacyclin (PGI2) analogue OP-4183, p38 mitogen-
activated protein kinase (MAPK) inhibitor FR167653, NO donor sodium nitroprusside, 
platelet-activating factor (PAF) antagonist E5880, calmodulin inhibitors, Ca2+ channel 
blockers such as nisoldipine, trophic factors, caspase or calpain inhibitors, S-
adenosylmethionine (SAM), insuline, or fructose-1,6-biphosphate (FBP) were introduced 
into UW preservation solution, with promising results (Casillas et al., 2006). However, none 
of these modifications to UW solution composition have found their way into routine 
clinical practice. For instance, studies aimed at enrichment of UW solution with caspase 
inhibitors showed that this prevents sinusoidal endothelial cells apoptosis (Vajdova et al., 
2002), but it has also been demonstrated that such inhibitors have little effect on necrosis, 
and this could mean no protection in the steatotic liver where the predominant form of cell 
death is necrosis (Selzner, 2003). Along this line, addition of precursors for ATP resynthesis 
such as SAM only resulted in a poor initial ATP recovery during liver reperfusion (Vajdova 
et al., 2002) (see Fig. 3). Insulin and FBP were recommended and added to UW preservation 
solution with the aim of stimulating glycolysis and modulating KC activity, respectively. 
However, further studies showed that these modifications in UW solution may exacerbate 
graft ischemic injury and decrease the graft survival rate in rat LT.  
The failure of UW solution enrichments could be related either to factors intrinsic to the 
drugs themselves (i.e. toxic side-effects, lack of specificity, etc.) or disagreement in their 
mechanisms of modulation. For instance, LY294002 was added to UW in order to maintain 
calcium homeostasis through the inhibition of phosphatidylinositol-3-OH kinase (PI3K) 
activity (see Fig. 3). Despite LY294002 reduces apoptosis in the grafts, the beneficial effects 
of the survival pathway activated by PI3K were also suppressed (Carini et al., 2004). 
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Additives to UW solution might further improve survival rate and graft viability if their 
concentration could be increased, but this is not always possible. For example, the solubility 
of FR167653 in UW solution was found to be limited. In addition, these additives are rinsed 
from the liver graft before implantation, so they should have prolonged action (Yoshinari et 
al., 2001). For instance, addition of precursors for ATP re-synthesis, such as S-
adenosylmethionine, only resulted in a poor ATP recovery during reperfusion, since they 
can be rescued only partially after liver flush before implantation (Vajdova et al., 2002). 
Another limitation is that suitable concentrations of additives, such as caspase inhibitor 
IDN-1965, can be achieved only with prolonged storage of the organ in the presence of the 
inhibitor (Natori et al., 1999). However, this exacerbates the cold ischemic injury.  
Numerous studies have reported equivalent patient and graft survival for deceased donor 
liver allografts preserved with UW and HTK solutions (Steawart et al., 2009). The reduced 
viscosity of HTK as compared to UW has been hypothesized to be protective against the 
development of biliary complications. However, the impact of HTK versus UW preservation 
on biliary complications remains unclear, as some centers report equivalent, increased or 
reduced rates of biliary complication with HTK preservation of deceased donor liver 
allografts (Feng et al., 2007; Steawart et al., 2009).  
Clinical studies indicated that HTK preservation was associated with higher odds or early 
graft loss as compared to UW preservation with a more pronounced effect on allograft with 
cold ischemia time over 8 h, donor after cardiac death allografts and donors over 70 years 
(Steawart et al., 2009). As previously reported, HTK is not so efficient for longer periods of 
cold ischemia causing a higher incidence of delayed graft function (Olschewski et al., 2008; 
Straatsburg et al., 2002)  
5.3 Gene therapy 
Advances in molecular biology provide new opportunities to reduce liver I/R injury by 
using gene therapy. To suppress the ROS burst, SOD and catalase have been transfected by 
either adenovirus, liposomes or polyethyleneglycol (Fan et al., 1999; Selzner, 2003). To 
inhibit apoptosis, overexpression of Bag-1 and Bcl-2, mainly by using adenovirus, has been 
tested (Selzner, 2003) (see Fig. 3). To limit neutrophil recruitment and activation, reduction 
in ICAM-1 expression was obtained by using liposomes. Cytoprotective strategies based on 
expression of genes such as HO-1, anti-inflammatory cytokine IL-13 and interleukin-1 
receptor antagonist (IL-1Ra) have been developed employing adenoviral or liposome 
vector (Casillas et al., 2006). Attempts have also been made to modulate the NFκB effect 
through adenoviral transfection of a mutant inhibitor of kappaB-alpha (IκBalpha), which 
would inhibit NFκB and ameliorate the hepatic inflammatory response to I/R (Fan et al., 
1999; Casillas et al., 2006) (see Fig. 3). However, there are a number of problems inherent in 
gene therapy, for example, vector toxicity, difficulties in increasing transfection efficiencies 
and protein expression at the appropriate time and site, and the problem of obtaining 
adequate mutants (in the case of NFκB) due to controversy about NFκB activation 
(Chaisson et al., 2002; Somia & Verma, 2000). Although non-viral vectors (such as naked 
DNA and liposomes) are likely to present fewer toxic or immunological problems, they 
suffer from inefficient gene transfer (Somia & Verma, 2000). In addition, LT is an 
emergency procedure in most cases, which leaves very little time to pre-treat the donor 
with genetic approaches.  
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6. Directions for the future 
New potential strategies that could be promissory in LT are now discussed. The present 
review will now centre on emerging protective strategies such as enrichments of UW 
solution and pharmacological treatments with favourable results in I/R injury but that up to 
now have not been tested in clinical LT. Moreover, we will discuss ischemic preconditioning 
taking into account the novel clinical reports that suggest the effectiveness of this surgical 
procedure in LT. 
6.1 Pharmacological treatments and preservation solutions 
6.1.1 Trimetazidine and AICAR 
Trimetazidine (TMZ), which has been used as an anti-ischemic drug in the heart for over 35 
years (Ikizler et al., 2003) reduced liver injury and improved liver regeneration and survival 
rate in partial hepatectomy under vascular occlusion (Casillas et al., 2006). TMZ has been 
used as an additive in UW solution to protect steatotic livers exposed to prolonged cold 
ischemia in an ex vivo model of hepatic ischemia (Ben Mosbah et al., 2006). This could be of 
interest since irreversible injury has been reported in liver grafts preserved in UW after 
prolonged cold ischemic periods (between 16 h to 24 h) (Ben Mosbah et al., 2006). Studies 
examining the underlying protective mechanisms of TMZ suggest that mitochondria, 
energy metabolism, oxidative stress and microcirculation might be important targets 
through which TMZ exerts its cytoprotective effect (Ben Mosbah et al., 2006; Ikizler et al., 
2003). Interestingly, these mechanisms are responsible for the vulnerability of steatotic livers 
to I/R. Similarly to the benefits of TMZ, the addition of AMPK activators to UW solutions 
such as 5-amino-4-imidazole carboxamide riboside (AICAR), protected steatotic livers 
against their vulnerability to I/R. TMZ, by means of AMPK, increased NO, thus protecting 
steatotic livers against their vulnerability to I/R injury (Ben Mosbah et al., 2006, 2007; 
Carrasco et al., 2005). Taking these observations into account, TMZ and AICAR may 
constitute new additives to UW solution in steatotic liver preservation, whereas a 
combination of both seems unnecessary. 
6.1.2 Modulators of renin-angiotensin system 
Previous researches have observed an important role for the renin-angiotensin system 
(RAS), known for its regulation of blood pressure and fluid homeostasis, in both I/R injury 
and liver regeneration after partial hepatectomy (Ramalho et al., 2002; 2009). Furthermore, 
angiotensin-converting enzyme (ACE) inhibitors (captopril and enalapril) and angiotensin II 
(Ang-II) type 1 receptor blockers (losartan and candesartan) reduced inflammatory response 
associated with I/R injury (Araya et al., 2002). In addition, ACE inhibitors (lisinopril, 
captopril and enalaprilat) promoted liver regeneration after partial hepatectomy (Ramalho 
et al., 2002). Candesartan, a potent and long-lasting Ang-II type 1 receptor antagonist, up-
regulated the hepatocyte growth factor (HGF), the most potent mitogen for mature 
hepatocytes (Araya et al., 2002). Steatotic livers against I/R. In conditions of partial 
hepatectomy under I/R, Angiotensin receptors (AT1R and AT2R) antagonists for steatotic 
livers improved regeneration in the remnant liver. AT1R antagonist, through NO inhibition, 
protected steatotic livers against oxidative stress and damage. The combination of AT1R and 
AT2R antagonists in steatotic livers showed stronger liver regeneration than either 
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antagonist used separately and also provided the same protection against damage as that 
afforded by AT1R antagonist alone. These results could be of clinical interest in liver surgery 
(Ramalho et al., 2009). BK seems to be a key mediator in the benefits of all the blockers of 
Ang II activity (ACE inhibitors, AT1R antagonists, and AT2R antagonists) in steatotic livers 
undergoing I/R (Casillas et al., 2008). In liver transplantation, Ang II is an appropriate 
therapeutic target only in non-steatotic livers. It was observed an upregulation of ACE2 in 
steatotic liver grafts, which was associated with decreased Ang II and high Ang-(1–7) levels. 
Ang-(1–7) receptor antagonist reduced necrotic cell death and increased survival in 
recipients transplanted with steatotic liver grafts. These results indicate a novel target for 
therapeutic interventions in liver transplantation within the RAS cascade, based on Ang- (1–7), 
which could be specific for this type of liver (Alfany et al., 2009). Further studies will be 
required to elucidate whether these strategies based on regulating RAS can be useful in 
hepatic I/R injury. ACE inhibitors are widely used in clinical practice. However, 
hepatotoxicity and cholestatic liver diseases have been reported under ACE inhibition 
(Casillas et al., 2008). Previous studies have indicated that losartan is as effective as captopril 
in its cardiovascular effects but has fewer adverse effects (Zhu et al., 2000). Thus, AT1R 
antagonists may be a safer protective pharmacologic strategy than ACE inhibitors for 
hepatic I/R injury. 
6.1.3 Modulators of activating pro-survival kinase cascades, PI3K-Akt and Erk 1/2 
pathway 
Trophic factors such as insulin-like growth factor (IGF), EGF, cardiotrophin-1 and fibroblast 
growth factor (FGF) have been shown to protect against I/R injury through the activation of 
phosphatidylinositol-3-OH kinase (PI3K)-Akt and p42/p44 extra-cellular signal-regulated 
kinases (Erk 1/2). This pathway has been implicated in cellular survival, through 
recruitment of anti-apoptotic protection pathways. PI3K-Akt has been shown to increase 
NO, inhibit opening of the MPT pore, and activate protein kinase C (PKC) and 
mitochondrial Raf-1, which has been shown to phosphorylate and inactivate the pro-
apoptotic factor, Bad. Activation of either the PI3K-Akt or the Erk 1/2 pathway inhibits the 
conformational change in Bax required for its translocation to the mitochondria. Moreover 
Erk 1/2 kinase activation has been shown to inhibit apoptosis, by inhibiting caspase 3 
activation and Akt activation can suppress the mitochondrial apoptotic death pathway by 
inactivating caspase 9. Interestingly, PI3K-Akt is a cell signalling mechanism also involved 
in the benefits of liver ischemic preconditioning in isolated hepatocytes. The modulation of 
therapeutic targets such as the anti-apoptotic pro-survival PI3K-Akt and Erk 1/2 kinase 
cascades could open new perspectives for limiting I/R injury associated with LT (Casillas et 
al., 2006).  
Cardiotrophin-1 (CT-1) and alpha-lipoic acid (LA) could be promising drugs against I/R 
injury associated with LT because their benefits on pro-survival kinase cascades. The 
pretreatment of isolated hepatocytes with the pro-apoptotic mediator transforming growth 
factor-beta stimulates CT-1 production. In addition, pretreatment with CT-1 protects rats 
against fulminant liver failure after subtotal hepatectomy. This protective effect was 
associated with reduced caspase-3 activity and activation of Erk1/2 and PI3K/Akt 
pathways (Bustos et al., 2003). Recent research points to the potential of preconditioning 
with LA for hepatic IRI, which is mediated via the PI3K/Akt pathway. However, neither  
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Bad nor eNOS phosphorylation was increased after LA pretreatment, suggesting a new 
mechanism by which LA exerts antinecrotic but not antiapoptotic action during hepatic I/R 
(Muller et al., 2003). This could be of special interest to protect steatotic liver grafts, given 
that necrosis rather than apoptosis is the predominant type of cell death in such cases. 
The results, based on isolated perfused liver, indicated that the addition of EGF and IGF-I 
(separately or in combination) to UW reduced hepatic injury and improved function in both 
liver types. A combination of EGF and IGF-I resulted in hepatic injury and function 
parameters in both liver types similar to those obtained by EGF and IGF-I separately. EGF 
increased IGF-I, and both additives up-regulated AKT in both liver types. This was 
associated with glycogen synthase kinase-3ǃ (GSK3ǃ) inhibition in non-steatotic livers and 
peroxisome proliferator-activated receptor gamma (PPARǄ) over-expression in steatotic 
livers. The benefits of EGF and IGF-I as additives in UW solution were also clearly seen in 
the LT model, because the presence of EGF and IGF-I (separately or in combination) in UW 
solution reduced hepatic injury and improved survival in recipients who underwent 
transplantation with steatotic and nonsteatotic liver grafts. Thus, EGF and IGF-I may 
constitute new additives to UW solution in steatotic and nonsteatotic liver preservation, 
whereas a combination of both seems unnecessary (Zaouali et al., 2010). 
6.2 Antiapoptotic strategies 
An interesting research in hepatic warm ischemia by Bailly-Maitre et al. has pointed to BAX 
inhibitor-1 (BI-1) as a regulator of the endoplasmic reticulum (ER) stress-mediated apoptosis 
pathway (Bailly et al., 2006). The results could lead to new strategies for reducing I/R injury 
associated with LT. Some mechanisms of ER stress-mediated apoptosis are briefly described 
below. During liver ischemia, hypoxia-induced ATP deficiency promotes the release of Ca2+ 
from ER to cytosol. The depletion of ER Ca2+ stores triggers downstream ER stress pathways 
that induce apoptosis. The pro-apoptotic Bcl-2 family members BAX and BAK, localized to 
the ER, also induce emptying of ER Ca2+ pools concomitantly with Ca2+ translocation into 
the mitochondria (Breckenridge et al., 2003). In addition, I/R initiates protein misfolding in 
the ER, which can activate a highly conserved unfolded protein response (UPR) signal 
transduction pathway. The UPR is characterized by coordinated activation of three ER 
transmembrane proteins, IRE1, PKR-like ER kinase (PERK) and activating transcription 
factor (ATF)-6. If the damage is so severe that homeostasis cannot be restored, ER stress 
signal transduction pathways ultimately initiate apoptosis (Oyadomari & Mori, 2004; Xu et 
al., 2005). The study by Bailly-Maitre indicated that the ER membrane protein BI-1 protects 
against apoptosis induced by ER stress. Compared to wild-type BI-1 mice, BI-1 knockout 
mice subjected to hepatic ischemia/reperfusion exhibited greater elevation in caspase-9 
activity, more activation of IRE1, ATF6 and JNK, and greater increases in expression of 
CHOP and spliced X-box binding protein 1 (XBP-1) (Bailly et al., 2006). Thus, strategies 
aimed at modulating BI-1 as well as other component of ER stress-mediated apoptosis could 
protect not only against ER stress but also against the mitochondrial-dependent apoptosis 
pathway. In liver, the small molecule chemical chaperones, 4-PBA and Tauroursodeoxycholic 
acid (TUDCA) protect against I/R-induced ER stress-mediated cell death in non-steatotic 
livers undergoing ischemic conditions (Falasca et al., 2001; Vilatoba et al., 2005). 4-PBA 
reduced inflammatory response, apoptosis and mortality in non-steatotic livers undergoing 
total hepatic ischemia (Vilatoba et al., 2005). The addition of TUDCA to UW preservation 
solution protected non-steatotic livers, specifically sinusoidal lining cells and hepatocytes 
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against cold ischemia injury (Falasca et al., 2001). Recent studies indicated that PBA, and 
especially TUDCA, reduced inflammation, apoptosis and necrosis, and improved liver 
regeneration in both steatotic and non-steatotic livers in partial hepatectomy under vascular 
occlusion. Both compounds, especially TUDCA, protected both liver types against ER 
damage, as they reduced the activation of two of the three pathways of UPR (namely 
inositol-requiring enzyme and PKR-like ER kinase) and their target molecules caspase 12,  
c-Jun N-terminal kinase and C/EBP homologous protein-10. Only TUDCA, possibly 
mediated by extracellular signal-regulated kinase upregulation, inactivated glycogen 
synthase kinase-3ǃ. This in turn, inactivated mitochondrial voltage-dependent anion 
channel, reduced Cyt c release from the mitochondria and caspase 9 activation and 
protected both liver types against mitochondrial damage (Ben Mosbah et al., 2010). Also, 
strategies aimed at modulating component of ER stress-mediated cell death could protect 
not only against ER stress but also against the mitochondrial-dependent apoptosis pathway. 
A recent study indicated that TUDCA reduced ER stress in steatotic liver transplantation. 
Further studies will be required to elucidate whether these chemical chaperones such as  
4-PBA and TUDCA could be considered as useful strategies in clinical LT. They have been 
used for clinical treatment of urea cycle disorders, cholestatic liver diseases and cirrhosis 
(Ben Mosbah et al., 2010). Results of clinical trials have shown that 4-PBA has few side 
effects and is safe for patients since it is well tolerated at high dose for long periods of time 
(Özcan et al., 2006). TUDCA is a derivate of an endogenous bile acid, and it has been safely 
used as a hepatoprotective agent in humans with cholestatic liver diseases (Falasca et al., 
2001).  
Recently, autophagy has been described to be activated in stress conditions to ensure cell 
survival by limiting necrosis or apoptosis in vivo. Autophagy is a catabolic pathway 
triggered following various stress conditions, such as starvation or transient hypoxia, and 
aimed to restore adequate intracellular ATP and aminoacids levels and to eliminate 
damaged organelles (Degli et al., 2011). Autophagy has been shown to retard cell death by 
suppressing ER stress. Thus, the possibility that activation of autophagy may be involved in 
ER stress attenuation in steatotic livers, and that the modulation of autophagy and ER stress 
can have beneficial effects in clinical LT should not be discarded. 
6.3 Omega-3 PUFAs 
Manipulation of the chemical composition of hepatic lipids may evolve as a useful strategy 
to expand the donor pool and improve the outcome after LT. Macrosteatotic livers disclosed 
an abnormal omega-6: omega-3 PUFA ratio that correlates with a microcirculatory defect 
that enhanced reperfusion injury (El-Badry et al., 2007). Therefore, normalization of the Ω-
6:Ω-3 FA ratio appears to be crucial for protection of the steatotic liver from reperfusion 
injury. Preoperative dietary omega-3 PUFAs protect macrosteatotic livers against 
reperfusion injury and might represent a valuable method to expand the live liver donor 
pool (El-Badry et al., 2007). Clavien et al., treated three live liver donors with moderate 
degrees of steatosis by oral administration of X-3 FAs. All donors showed a significant 
reduction of hepatic fatty infiltration within one month. Subsequently, LT was carried out 
for three candidates with uneventful outcomes for both donors and recipients. A very 
promising option to prevent post-transplant complications appears to be the use of a 
pretreatment with X- 3 FAs. However, the approach is only feasible in living donation since 
requires oral administration of X-3 FAs before organ procurement (McCormack et al., 2011).  
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Due to large inconsistencies in the qualitative and quantitative measurement of fat deposits 
in the liver, new techniques of assessment of steatosis are needed. Computerized programs 
have been developed to more objectively quantitate hepatic steatosis by determining the 
area occupied by lipid droplets in a given field of a liver section (El-Badry et al., 2009). 
However, these quantitative methods provide information only on the total amount of fat, 
omitting any data on the chemical composition of hepatic lipids. Therefore, novel and 
objective tools, such as measurement of the X-6 and X-3 FAs and prostanoid levels in liver 
biopsy samples, may help prediction of the magnitude of reperfusion injury (McCormack et 
al., 2011). 
6.4 Adipocytokines derived from liver and/or adipose tissue 
To date, adipose tissue has been considered the major site for endogenous adiponectin 
production, although there are other potential sources, including the liver (Massip-Salcedo 
et al., 2008; Neumeier et al., 2006). A recent study indicated that steatotic livers can generate 
adiponectin as a consequence of I/R (Massip-Salcedo et al., 2008). The role of adiponectin in 
hepatic I/R injury remains unclear. Adiponectin silent small interfering RNA (siRNA) 
treatment decreased oxidative stress and hepatic injury in steatotic livers. PPAR-α agonists 
as well as ischemic preconditioning (PC), through PPAR-α, inhibited mitogen-activated 
protein kinase expression following I/R. This in turn inhibited the accumulation of 
adiponectin in steatotic livers and reduced its negative effects on oxidative stress and 
hepatic injury (Massip-Salcedo et al., 2008). However, another study by Man et al., 2006 in 
small fatty grafts, adiponectin treatment exerted anti-inflammatory effects that down-
regulated TNF-α mRNA and vasoregulatory effects that improved the microcirculation. 
Adiponectin anti-inflammatory effects also include the activation of cell survival signaling 
via the phosphorylation of Akt and the stimulation of NO production. Additionally, the 
studies by Man et al., 2006 showed the anti-obesity and proliferative properties of 
adiponectin in small fatty transplants. Thus, on the basis of the different results reported to 
date in hepatic I/R, it is difficult to discern whether we should aim to inhibit adiponectin, or 
administer adiponectin to protect steatotic livers against cold ischemia associated with 
transplantation. 
Levels of adiponectin are reduced in obese subjects (Bugianesi et al., 2005; Targher et al., 
2006; Weyer et al., 2001) and in experimental models of fatty livers, irrespective of the type 
of steatosis (induced by diet or alcohol) (Rogers et al., 2008; Xu et al., 2003). Indeed, in a 
cohort of 68 obese individuals, serum levels of adiponectin significantly predicted hepatic 
steatosis and hepatic damage (Schäffler et al., 2005; Targher et al., 2004). Research aimed at 
identifying prognostic factors in LT are both necessary and relevant. Further investigations 
will be required to elucidate whether measurements of adiponectin in serum, a non-invasive 
tool, might predict the severity of steatosis and liver damage and contribute to the 
identification of steatotic liver donors with a high risk for transplantation. The decision to 
implant or reject a steatotic liver is difficult due to the risk of impaired graft function or even 
failure after implantation. How much fat, and what types of fat, represent a significant risks 
for primary non-function of the graft remain under debate. The assessment of donor liver fat 
is a difficult task for the transplant team due to large inconsistencies in the qualitative and 
quantitative measurement of fat deposits in the liver (El-Badry et al., 2009; McCormack et 
al., 2011).  
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Retinol binding protein 4 (RBP4) is an adipokine synthesized by the liver, whose known 
function is to transport retinol in circulation. However, the role of RBP4 in the liver is largely 
unknown. A recent study indicated that steatotic liver grafts were found to be more 
vulnerable to the down-regulation of RBP4 and the over-expression of PPARǄ. RBP4 
treatment (through AMP-activated protein kinase (AMPK) induction) reduced PPARǄ over-
expression, thus protecting steatotic liver grafts against I/R injury associated with 
transplantation. In terms of clinical application, therapies based on RBP4 treatment and 
PPARǄ antagonists might open new avenues for steatotic LT and improve the initial 
conditions of donor livers with low steatosis that are available for transplantation. (Casillas 
et al., 2011). 
6.5 Surgical strategies  
The response of hepatocyte to ischemia never ceases to be surprising. In fact, contrary to 
what might be expected, the induction of consecutive periods of ischemia to the liver does 
not provoque an additive effect in terms of the hepatocyte lesion. Murry et al. have reported 
that ischemic PC based on a brief period of ischemia followed by a short interval of 
reperfusion prior to a prolonged ischemic stress protects against I/R injury (Murry et al., 
1986). The molecular basis for PC consists of a sequence of events: in response to the triggers 
of PC, a signal must be rapidly generated which is then transduced into an intracellular 
message leading to the amplification of the effector mechanism of protection (Cutrin et al., 
2002; Serafin et al., 2004b). As in the pathophysiology of hepatic I/R, in the modulation of 
hepatic injury induced by IP there is a complex interaction between different cell types.  
The present review is focused on some of the proposed mechanisms leading to the 
development of hepatocyte resistance to I/R injury following hepatic PC (see Fig. 4). 
Vasoactive substances such as adenosine, NO, bradykinin, etc, have been considered as the 
major players in triggering preconditioning (Cutrin et al., 2002). In addition to the 
extracellular mediators, PC involves activation of intracellular messengers such as PKC, 
AMPK, p38 MAPK, Ik kinase; signal transducer and activator of transcription-3 (STAT3) 
and transcription factors including NFκB and heat shock transcription factor 1 (HSF1) 
(Carini & Albano, 2003; Selzner, 2003) (see Fig. 4). The downstream consequences of these 
pathways could be cytoprotective by abrogation of cell death pathways, stimulating 
antioxidant and other cellular protective mechanisms including MnSOD and heat shock 
proteins (HSPs), and by initiating entry into the cell cycle (Cutrin et al., 2002; Selzner, 2003). 
The benefits of PC on energy metabolism, inflammatory mediators including ROS and TNF, 
mitochondrial dysfunction, KC activation, and microcirculatory disorders associated with 
I/R injury have also been described (Casillas et al., 2006; Massip-Salcedo et al., 2007). PC via 
AMPK activation, reduced the ATP depletion thus attenuating the accumulation of 
glycolytic intermediates and lactate production during hepatic sustained ischemia (Peralta 
et al., 2000b). The benefits of PC on oxidative stress could be explained by the induction of 
antioxidants, such as SOD and HSPs as well as by its effect on XDH/XOD (Carini & Albano, 
2003; Casillas et al., 2006; Massip-Salcedo et al., 2007). PC reduced the accumulation of 
xanthine during ischemia and prevented the conversion of XDH to XOD, thus preventing 
the deleterious effect of this ROS generating system on liver (Fernández et al., 2002; Serafin 
et al., 2004b) (see Fig. 4). It is possible that NFkB and p38 MAPK-regulated transcription 
factors (ATF-2 and MEF2C) might be responsible for inducing the expression of protective 
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genes, including SOD. HSPs induced by PC might contribute to improve membrane 
potential and respiratory control in hepatic mitochondria, allowing a faster recovery of ATP 
on reoxygenation (Carini & Albano, 2003; Massip-Salcedo et al., 2007). The modulation of 
inflammatory response by hepatic PC has been also reported in different experimental 
models of warm and cold hepatic ischemia. PC reduces neutrophil accumulation, the 
generation of different cytokines and interleukins including TNF and IL-1 (Casillas et al., 
2006; Cutrin et al., 2002; Massip-Salcedo et al., 2007). The benefits of PC were also observed 
on hepatic microcirculation by inhibiting the effects of different vasoconstrictor mediators 
such as ETs, thus ameliorating sinusoidal perfusion and microvascular dysfunction (Peralta 
et al., 1996; Peralta et al., 1999a). The benefits of PC regulating Ang II and adipocytokines 
such as adiponectin and RBP4 have been also reported in hepatic I/R. PC, through PPARα 
inhibits adiponectin accumulation in steatotic livers and adiponectin-worsening effects on 
oxidative stress and hepatic injury in hepatic resactions (Massip-Salcedo et al., 2008). In liver 
transplantation PC, which increases RBP4 levels, reduced PPARǄ levels and hepatic injury 
in steatotic livers (Casillas et al., 2011). As ER stress activates an adaptive response to  
injury, modulating ER stress before transplantation by PC could improve the grafted organ 
viability (see Fig. 4). Along these lines, it has been proposed that induction of ER  
chaperones, particularly of BiP, underlies the phenomenon of PC in the heart, in which 
exposure to a transient episode of brief ischemia provides subsequent protection from a  
 
Fig. 4. Molecular basis of the ischemic preconditioning protection. (Carini & Albano, 2003; 
Casillas et al., 2006; Cutrin et al., 2002; Fernández et al., 2002; Massip-Salcedo et al., 2007, 
2008; Peralta et al., 1996, 1999a, 2000b; Selzner, 2003; Serafin et al., 2004b) 
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sustained ischemic challenge (Kim et al., 2008). It is tempting to speculate that PC activates 
the UPR, particularly the adaptive and pro-survival aspects of ER stress (Pallet et al., 2009). 
Since the effectiveness of PC was first described, numerous efforts have been made to find 
strategies capable of mimicking its beneficial effects. One of these strategies is known as heat 
shock preconditioning, in which the organ or the whole body is temporarily exposed to 
hyperthermia prior to hepatic ischemia. Chemical preconditioning with either doxorubicine, 
atrial natriuretic peptide or oxidants decreases hepatic injury in several experimental 
models of I/R. However, their possible clinical application seems limited owing to 
difficulties in implementing them in clinical practice, toxicity problems and the side-effects 
that have been identified (Casillas et al., 2006; Massip-Salcedo et al., 2007; Peralta et al., 
1999a). 
The benefits of PC observed in experimental models of hepatic warm and cold ischemia 
created the need for human trials of PC. To date, PC has been successfully applied in human 
liver resections in both steatotic and non-steatotic livers. The effectiveness of PC in hepatic 
surgery was first reported by Clavien et al., 2003, but unfortunately, in this study, it proved 
ineffective in elderly patients. It is well known that the impact of cold ischemia on organ 
function becomes even more significant as the age of the donor increases (Busuttil & Tanaka, 
2003). Recent research indicates that melatonin prevents oxidative stress and inflammatory 
response in hepatocytes from elderly rats and this could improve the viability of liver grafts 
from elderly donors and increase the effectiveness of PC (Castillo et al., 2005).  
Prevention of post-hepatectomy liver insufficiency by PC, particularly in patients with 
cirrhotic or steatotic livers has also been demonstrated (Nuzzo et al., 2004). A clinical study 
by Koneru and colleagues showed no effects of PC on cadaveric donor livers compared with 
controls. However, the study consisted of clamping the hepatic vessels for a period of 5 min, 
and as the authors concluded, that may be insufficient to obtain a beneficial effect from PC 
(Koneru et al., 2005). Another clinical study carried out by Azoulay and colleagues using the 
model of cadaveric whole liver transplantation showed that PC based on 10 min of ischemia 
was associated with better tolerance to ischemia. However, this was at the price of decreased 
early function (Azoulay et al., 2005). Beginning this year, Jassem and colleagues concluded 
that 10 min of preconditioning was effective to protect cadaveric donor allografts from cold 
ischemia, reduced inflammatory response and resulted in better graft function (Jassem et al., 
2006). Further randomised clinical studies are necessary to confirm whether PC is 
appropriate for LT in clinical practice. The potential applications of PC in human LT are 
numerous. PC also has the potential to increase the number of organs suitable for LT since it 
can improve the outcome for marginal grafts that would not otherwise have been 
transplanted. Its benefits to reduce the vulnerability of steatotic grafts to I/R injury have 
also been reported in different experimental studies of LT (Carrasco et al., 2005; Fernández 
et al., 2004). Interestingly, the effectiveness of PC in clinical practice in major liver 
hepatectomy opens up new possibilities in living donor liver transplantation, since the 
ischemia period is similar in both surgical procedures. Moreover, PC increases liver 
regeneration, the most critical aspect to be considered in living donor liver transplantation 
(Franco et al., 2004). Again, PC may also have a role in the transplantation of small grafts 
whose pathophysiology overlaps with I/R injury. In fact, a study published by Barrier et al., 
2005 has shown the benefits of PC in transplantation from living human liver donors. PC is 
easy to apply, inexpensive and does not require the use of drugs with potential side effects. 
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One disadvantage of PC is that it requires a period of pre-ischemic manipulation for organ 
protection. 
7. Conclusion and perspectives 
The hope of finding new surgical and pharmacological therapeutic applications provides a 
strong impetus to identify the mechanisms responsible for the failure of fatty livers. We 
must continue conducting researches attempting to improve the outcomes of LT using fatty 
liver grafts. Before a complete definition of a successful therapeutic strategy based on 
regulating hepatic I/R injury is stated, several additional points need to be addressed. The 
effects of the new potential protective strategies (TMZ, AICAR, RAS modulators, PI3K and 
ERK1/2 modulators, anti-apoptotic strategies, omega-3 PUFA, adiponectin, RBP4 and PC) 
on the pathways involved in the inflammatory process and lipid metabolism have only just 
been mapped. The success of these protective strategies might depend on the surgical 
procedure. Moreover, the response of different type of liver to these treatments might differ 
and involve different signal transduction pathways that are at present marginally 
understood. Whether the above-mentioned approaches can be translated into as viable 
options in the clinical practice remain unknown, but further researches are required to 
optimize the their use (e.g. dose, pharmacokinetics…etc). Such approaches have the 
potential to increase the number of organs suitable for transplantation, since they may 
improve the outcomes of marginal grafts that would not otherwise have been used.  
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